Rodman & Renshaw initiated coverage of Heron Therapeutics with a Buy rating and $7 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRTX:
- Heron Therapeutics Submits ZYNRELEF® Supplement to FDA
- Heron announces PAS submission to FDA for ZYNRELEF
- Heron Therapeutics sees FY24 adjusted EBITDA ($22.0M)-$3.0M
- Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
- Heron Therapeutics reports Q1 EPS (2c), consensus (9c)
Questions or Comments about the article? Write to editor@tipranks.com